International Journal of Hematology and Oncology
2024, Vol 34, Num 1 Page(s): 028-034
| Back | Table of Contents | PDF | Mail to Author | |
The Prognostic Value of the HALP Score and Inflammatory Index in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Second-Generation Anti-Androgens
Yasemin BAKKAL TEMI1, Elif SAHIN2, Umut KEFELI1, Devrim CABUK1, Kazim UYGUN1
1Kocaeli University Faculty of Medicine, Department of Internal Medicine and Medical Oncology, Kocaeli
2Kocaeli City Hospital, Department of Internal Medicine and Medical Oncology, Kocaeli
Keywords: HALP score, Prostate cancer, Survival
We evaluated the prognostic value of the hemoglobin albumin lymphocyte and platelet (HALP) score and inflammatory index in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone and enzalutamide. In this retrospective study, 136 patients with mCRPC were treated with enzalutamide and abiraterone between January 2018 and March 2023; all data were collected from the hospital database. The HALP score and neutrophil-to-lymphocyte ratio (NLR) were calculated from baseline blood tests, and their impacts on progression-free survival (PFS) and overall survival (OS) were analyzed. Patients with lower HALP scores (≤ 23.78) exhibited a significantly reduced OS of 31.2 months compared with those with higher scores (> 23.78, OS: 63.9 months). Similarly, patients with a higher NLR (> 2.15) showed a poorer OS of 38.4 months compared with those with a lower NLR (≤ 2.15, OS: 70.1 months). The results were significant in terms of PFS. Patients with lower HALP scores had a PFS of 22.9 months, whereas those with higher scores had a longer PFS of 43.2 months. For NLR, patients with a score ≤ 2.15 had a PFS of 43.0 months, whereas those with scores > 2.15 had a PFS of 33.5 months. These findings, supported by ROC curve analysis, Kaplan–Meier estimates, and Cox regression analysis, underscore the significance of the HALP score and NLR as prognostic factors. This study highlights the HALP score and NLR as effective, low-cost prognostic markers for patients with mCRPC undergoing treatment with next-generation anti-androgens. These biomarkers can predict patient outcomes and guiding treatment strategies.
Yasemin BAKKAL TEMI1, Elif SAHIN2, Umut KEFELI1, Devrim CABUK1, Kazim UYGUN1
1Kocaeli University Faculty of Medicine, Department of Internal Medicine and Medical Oncology, Kocaeli
2Kocaeli City Hospital, Department of Internal Medicine and Medical Oncology, Kocaeli
Keywords: HALP score, Prostate cancer, Survival
We evaluated the prognostic value of the hemoglobin albumin lymphocyte and platelet (HALP) score and inflammatory index in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone and enzalutamide. In this retrospective study, 136 patients with mCRPC were treated with enzalutamide and abiraterone between January 2018 and March 2023; all data were collected from the hospital database. The HALP score and neutrophil-to-lymphocyte ratio (NLR) were calculated from baseline blood tests, and their impacts on progression-free survival (PFS) and overall survival (OS) were analyzed. Patients with lower HALP scores (≤ 23.78) exhibited a significantly reduced OS of 31.2 months compared with those with higher scores (> 23.78, OS: 63.9 months). Similarly, patients with a higher NLR (> 2.15) showed a poorer OS of 38.4 months compared with those with a lower NLR (≤ 2.15, OS: 70.1 months). The results were significant in terms of PFS. Patients with lower HALP scores had a PFS of 22.9 months, whereas those with higher scores had a longer PFS of 43.2 months. For NLR, patients with a score ≤ 2.15 had a PFS of 43.0 months, whereas those with scores > 2.15 had a PFS of 33.5 months. These findings, supported by ROC curve analysis, Kaplan–Meier estimates, and Cox regression analysis, underscore the significance of the HALP score and NLR as prognostic factors. This study highlights the HALP score and NLR as effective, low-cost prognostic markers for patients with mCRPC undergoing treatment with next-generation anti-androgens. These biomarkers can predict patient outcomes and guiding treatment strategies.
| Back | Table of Contents | PDF | Mail to Author | |